OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Publication Date
Release Date
2023
(2)
2022
(2)
2021
(2)
2019
(2)
2020
(1)
2016
(1)
2012
(1)
2010
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Not available
S-EPMC3031379
|
biostudies-literature
Cite
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Not available
S-EPMC6854441
|
biostudies-literature
Cite
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Not available
S-EPMC6772147
|
biostudies-literature
Cite
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Not available
S-EPMC3392072
|
biostudies-literature
Cite
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Not available
S-EPMC8601389
|
biostudies-literature
Cite
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
Not available
S-EPMC8197746
|
biostudies-literature
Cite
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Not available
S-EPMC10644097
|
biostudies-literature
Cite
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Not available
S-EPMC10337122
|
biostudies-literature
Cite
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Not available
S-EPMC5524541
|
biostudies-literature
Cite
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Not available
S-EPMC9243087
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets